The COVID-19 pandemic may have sparked fresh interest in vaccines research, but France’s Valneva SE was already developing a suite of vaccines for relatively neglected infectious diseases, and positive top-line Phase III results for its investigational chikungunya vaccine VLA1553 is the latest data to be unveiled for its pioneering candidates.
Valneva’s progress has received significant backing from investors, with the Euronext-listed company also moving onto the US’s NASDAQ this May, along with a $107.6m global offering
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?